EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Current advances in platelet-rich plasma therapy for erectile dysfunction: a meta-analysis of randomized controlled trials

Dayan Jacob iD, Jack Hay, Muhammad Shariq Rahemtoola, Simone Sim, Lois Libretto, Elia Abou Chawareb iD, Muhammed Hammad, Mohamed Mubarak iD, Faysal Yafi, Ian Pearce, Vaibhav Modgil

The Journal of Sexual Medicine · 05.01.2026 · 23 (1)

DOI: 10.1093/jsxmed/qdaf325 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift The Journal of Sexual Medicine, online erschienen am 25.11.2025. Verfasst von Dayan Jacob und 10 weiteren Autor:innen. Beteiligte Einrichtung: Manchester Andrology Research Collaborative (MARC), Department of Urology, Manchester, M13 9WL, United Kingdom. Hauptthemen laut MEDLINE: Platelet-Rich Plasma, Erectile Dysfunction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Erectile dysfunction (ED) is a prevalent condition with multifactorial etiology and significant impact on men’s quality of life. Although standard therapies—such as phosphodiesterase type 5 inhibitors, vacuum devices, and penile prostheses—offer symptomatic relief, they do not address the underlying pathophysiology. Platelet-rich plasma (PRP), an autologous concentration of platelets and growth factors, has emerged as a potential regenerative treatment that may promote neurovascular repair and restore erectile function.

Aim

To evaluate the efficacy and safety of PRP monotherapy for the treatment of erectile dysfunction through a systematic review and meta-analysis of randomized controlled trials (RCTs).

Methods

Following PRISMA guidelines, a comprehensive search of PubMed, EMBASE, Google Scholar, Cochrane Library, Scopus, and Web of Science was performed for RCTs assessing intracavernosal PRP injections in men with ED. Studies combining PRP with other regenerative therapies were excluded. Data were synthesized using a random-effects model to generate pooled standardized mean differences (SMDs) in International Index of Erectile Function (IIEF) scores at 1, 3, and 6 months. Risk of bias was assessed using the Cochrane RoB 2 tool, and certainty of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework.

Results

Seven RCTs including 512 participants were analyzed. PRP injection volumes ranged from 5 to 10 mL across 2-4 sessions. At 1 month, pooled SMD in IIEF was 0.28 (95% CI −0.11 to 0.67, P = .16); at 3 months, it was 0.29 (95% CI −0.08 to 0.67, P < .05); and at 6 months, it was 0.36 (95% CI −0.09 to 0.81, P = .12). Heterogeneity was high (I2 = 74%-83%) across time points. Subgroup analyses showed no significant difference by risk of bias. PRP was well tolerated, with only isolated mild adverse events (hematoma, plaque formation) reported.

Conclusion

Current evidence does not support a consistent, clinically meaningful improvement in erectile function with PRP monotherapy compared with placebo. Despite an encouraging mechanistic rationale and safety profile, the high heterogeneity, small sample sizes, and methodological limitations of existing RCTs limit confidence in efficacy. Larger, standardized, double-blind trials with rigorous protocols are needed to clarify the role of PRP in ED management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet-Rich PlasmaErectile DysfunctionHumansMaleRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

PRP therapyerectile dysfunctionplatelet-rich plasmaregenerative medicinesexual health

Autor:innen und Institutionen

  • Manchester Andrology Research Collaborative (MARC), Department of Urology, Manchester, M13 9WL, United Kingdom.
  • University of California, Department of Urology, Irvine, California, 92868, United States.

ORCID-Profile: Dayan Jacob, Elia Abou Chawareb, Mohamed Mubarak

Zitieren

APA

Jacob, D., Hay, J., Rahemtoola, M. S., Sim, S., Libretto, L., Chawareb, E. A., Hammad, M., Mubarak, M., Yafi, F., Pearce, I., & Modgil, V. (2026). Current advances in platelet-rich plasma therapy for erectile dysfunction: a meta-analysis of randomized controlled trials. The Journal of Sexual Medicine, 23(1). https://doi.org/10.1093/jsxmed/qdaf325

Vancouver

Jacob D, Hay J, Rahemtoola MS, Sim S, Libretto L, Chawareb EA, et al. Current advances in platelet-rich plasma therapy for erectile dysfunction: a meta-analysis of randomized controlled trials. The Journal of Sexual Medicine. 2026;23(1). doi:10.1093/jsxmed/qdaf325

BibTeX
@article{Jacob2026,
  author = {Jacob, Dayan and Hay, Jack and Rahemtoola, Muhammad Shariq and Sim, Simone and Libretto, Lois and Chawareb, Elia Abou and Hammad, Muhammed and Mubarak, Mohamed and Yafi, Faysal and Pearce, Ian and Modgil, Vaibhav},
  title = {Current advances in platelet-rich plasma therapy for erectile dysfunction: a meta-analysis of randomized controlled trials},
  journal = {The Journal of Sexual Medicine},
  year = {2026},
  volume = {23},
  number = {1},
  doi = {10.1093/jsxmed/qdaf325}
}
Kostenlos starten →